Collectively, our findings suggest that the inhibition of FOXM1 Y575 phosphorylation leads to significant suppression of tumor growth, suggesting that ABL1 kinase inhibitors could be potential clinical agents for FOXM1-overexpressing tumor therapy. The gene discussed is FOXM1; the disease is neoplasm.